BioCentury
ARTICLE | Company News

Otsuka's Avanir to terminate Onzetra license

December 21, 2018 7:27 PM UTC

OptiNose Inc. (NASDAQ:OPTN) said it received written notice from Avanir Pharmaceuticals Inc. that the latter intends to terminate, effective March 10, a license granting it rights to develop and commercialize migraine drug Onzetra Xsail in the U.S., Canada and Mexico (see "Avanir, OptiNose deal").

Avanir is now part of Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan)...